University School of Medicine, Nis, Serbia.
Ren Fail. 2010 Jan;32(2):259-68. doi: 10.3109/08860221003599759.
The strong need for the discovery of novel disease markers together with the development of high-throughput techniques that provide highly sensitive analysis of protein content in tissues and bodily fluids, using proteomics, has opened the completely new chapter in biomarker discovery. The detection of biomarkers based on urinary proteome analysis is rapidly advancing and may provide new tools to improve non-invasive diagnostics, prognostics, and therapy enhancement. As a tool for biomarker discovery, urinary proteomics is especially fruitful in the area of early diagnostics and differentiation of renal damage, and it possesses enormous potential for improving and expanding non-invasive cancer diagnostics. An abundance of urinary proteins could provide a wide variety of biomarkers for the diagnosis and follow-up of many systemic diseases as well. This article reviews the utility of urinary proteomics for biomarker discovery from the perspective of clinical application. Despite huge potential and prompt development of urinary proteomics, many challenges are still in front of us. Research effort and financial investment have to be oriented on providing strategies for exceeding current methodological and technical obstacles in a way to ensure the successful validation and implementation of newly discovered urinary biomarkers. The result is expected to be the development of new non-invasive tests and procedures able to guarantee higher efficiency of patient care and provide needed personalized medical approach.
对新型疾病标志物的强烈需求，以及高通量技术的发展，利用蛋白质组学对组织和体液中的蛋白质含量进行高度敏感的分析，这为生物标志物的发现开辟了全新的篇章。基于尿液蛋白质组分析的生物标志物检测正在迅速发展，可能为改善非侵入性诊断、预后和治疗提供新的工具。作为生物标志物发现的工具，尿液蛋白质组学在早期诊断和肾脏损伤的区分方面尤其富有成效，并且在改善和扩展非侵入性癌症诊断方面具有巨大的潜力。大量的尿液蛋白质可以为许多系统性疾病的诊断和随访提供广泛的生物标志物。本文从临床应用的角度综述了尿液蛋白质组学在生物标志物发现中的应用。尽管尿液蛋白质组学具有巨大的潜力和迅速的发展，但我们仍然面临许多挑战。研究工作和资金投入必须着眼于提供策略，以克服当前的方法和技术障碍，确保新发现的尿液生物标志物的成功验证和实施。其结果有望开发出新的非侵入性测试和程序，能够保证更高的患者护理效率，并提供所需的个性化医疗方法。
